Hoshina Katsuyuki, Shigematsu Kunihiro, Hosaka Akihiro, Okamoto Hiroyuki, Miyata Tetsuro, Watanabe Toshiaki
aDivision of Vascular Surgery, Department of Surgery bDivision of Colon and Rectal Surgery, Department of Surgery, The University of Tokyo, Tokyo, Japan.
Blood Coagul Fibrinolysis. 2014 Jun;25(4):389-91. doi: 10.1097/MBC.0000000000000031.
Aortic aneurysms are sometimes accompanied with disseminated intravascular coagulation (DIC). The definitive treatment of DIC is removal of underlying disease; surgical repair for the aortic aneurysms. Heparin, anticoagulant and other antifibrinolytic agents have been administered preoperatively to alleviate DIC whose bleeding tendency could cause high mortality and morbidity; however, their effectiveness was indeterminate. An 84-year-old man was presented with abdominal aortic aneurysm accompanied by DIC and underwent aneurysmectomy. After having confirmed that combined use of heparin and gabexate mesilate was ineffective, we used recombinant human soluble thrombomodulin (rhsTM), which has been reported to be more effective and safer than the heparin, for a week preoperatively, and demonstrated dramatic improvement of DIC. RhsTM should be a novel powerful therapeutic option for aneurysm-induced DIC.
主动脉瘤有时会伴有弥散性血管内凝血(DIC)。DIC的 definitive治疗方法是去除潜在疾病,即对主动脉瘤进行手术修复。术前已使用肝素、抗凝剂和其他抗纤溶药物来缓解DIC,因为其出血倾向可能导致高死亡率和发病率;然而,它们的有效性并不确定。一名84岁男性因腹主动脉瘤伴DIC就诊并接受了动脉瘤切除术。在确认肝素和甲磺酸加贝酯联合使用无效后,我们术前使用了重组人可溶性血栓调节蛋白(rhsTM),据报道其比肝素更有效、更安全,使用一周后DIC有显著改善。RhsTM应该是动脉瘤诱发的DIC的一种新型有效治疗选择。